EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

CLDN18.2 CAR‐derived Extracellular Vesicle Immunotherapy Improves Outcome in Murine Pancreatic Cancer

Yue Qing, Ke Jiang, Hua Jiang, Yaru Zhao, Chu-Hu Lai, Alexandra Aicher, Zonghai Li, Christopher Heeschen iD

Advanced Healthcare Materials · 2025-06 · 14 (16)

DOI: 10.1002/adhm.202500546 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 19.05.2025. Verfasst von Yue Qing und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. Hauptthemen laut MEDLINE: Extracellular Vesicles, Pancreatic Neoplasms, Claudins, Immunotherapy, Adoptive. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Jilin Province, Hsinchu Science Park Bureau, Ministry of Science and Technology, Taiwan, Fondazione AIRC per la ricerca sul cancro ETS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with no current effective treatment options. Chimeric antigen receptor (CAR) T cell therapy represents a powerful immunotherapeutic approach but faces major limitations in PDAC due to complex manufacturing and reduces efficacy within the highly immunosuppressive tumor microenvironment (TME). Small extracellular vesicles (sEVs) derived from CAR‐T cells present a novel strategy to address these challenges. Here, CLDN18.2 CAR‐T cells are used to generate CAR‐sEVs via ultracentrifugation. The purified CAR‐sEVs exhibit typical sEV size and morphology, containing established sEV markers, and carry functional CAR proteins along with cytotoxic molecules such as granzyme B. In vitro, CAR‐sEVs displays potent cytotoxic activity against murine CLDN18.2 + PDAC cells, whereas no significant effects are observed in CLDN18.2 − non‐transformed cells. In an aggressive orthotopic murine PDAC model, CAR‐sEV administration reduces tumor growth as measured by bioluminescence imaging and significantly extends survival. Notably, CAR‐sEVs also significantly prolong survival compared to treatment with conventional CLDN18.2‐targeting CAR‐T cells, further supporting their therapeutic potential. Moreover, unlike CAR‐T cells, CAR‐sEVs do not induce systemic IL‐6 release in vivo. These findings position CLDN18.2 CAR‐sEVs as a promising therapeutic modality for PDAC, offering an innovative and potentially safer platform for solid tumor immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extracellular VesiclesPancreatic NeoplasmsClaudinsImmunotherapy, AdoptiveReceptors, Chimeric AntigenCarcinoma, Pancreatic DuctalImmunotherapyAnimalsMiceCell Line, TumorHumansTumor MicroenvironmentFemale

Stichwörter der Autor:innen

CAR‐T cellsexosomesextracellular vesiclespancreatic ductal adenocarcinoma

Substanzen

ClaudinsReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
  • State Key Laboratory of Systems Medicine for Cancer, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
  • CARsgen Therapeutics, Shanghai, 200231, China.
  • Precision Immunotherapy, Graduate Institute of Biomedical Sciences, China Medical University, Taichung, 404328, Taiwan.
  • Pancreatic Cancer Heterogeneity, Candiolo Cancer Institute - FPO - IRCCS, Candiolo (TO), 10060, Italy.

ORCID-Profile: Christopher Heeschen

Förderung

  • Natural Science Foundation of Jilin Province
  • Hsinchu Science Park Bureau, Ministry of Science and Technology, Taiwan
  • Fondazione AIRC per la ricerca sul cancro ETS
  • H2020 European Research Council
  • National Natural Science Foundation of China-Xinjiang Joint Fund

Zitieren

APA

Qing, Y., Jiang, K., Jiang, H., Zhao, Y., Lai, C. H., Aicher, A., Li, Z., & Heeschen, C. (2025). CLDN18.2 CAR‐derived Extracellular Vesicle Immunotherapy Improves Outcome in Murine Pancreatic Cancer. Advanced Healthcare Materials, 14(16). https://doi.org/10.1002/adhm.202500546

Vancouver

Qing Y, Jiang K, Jiang H, Zhao Y, Lai CH, Aicher A, et al. CLDN18.2 CAR‐derived Extracellular Vesicle Immunotherapy Improves Outcome in Murine Pancreatic Cancer. Advanced Healthcare Materials. 2025;14(16). doi:10.1002/adhm.202500546

BibTeX
@article{Qing2025,
  author = {Qing, Yue and Jiang, Ke and Jiang, Hua and Zhao, Yaru and Lai, Chu-Hu and Aicher, Alexandra and Li, Zonghai and Heeschen, Christopher},
  title = {CLDN18.2 CAR‐derived Extracellular Vesicle Immunotherapy Improves Outcome in Murine Pancreatic Cancer},
  journal = {Advanced Healthcare Materials},
  year = {2025},
  volume = {14},
  number = {16},
  doi = {10.1002/adhm.202500546}
}
Kostenlos starten →